Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Ebixa (memantine) approved for the treatment of moderate Alzheimer’s disease

14.10.2005


Ebixa extends its indication to become the only drug for moderate and severe Alzheimer’s disease.

The Committee for Medicinal Products for Human Use (CHMP) announced late last night its decision to extend Ebixa’s current indication (moderately severe to severe disease) to include moderate stages of Alzheimer’s disease (AD). Upon implementation of this approval by the European Union Commission, Ebixa will become the first Alzheimer’s drug in Europe to cover the moderate to severe stages of the disease.

In meta-analyses from six international phase III placebo-controlled six-month studies, patients with moderate to severe Alzheimer’s disease (MMSE total score at baseline below 20) showed statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains. Further analysis showed that twice as many memantine-treated patients showed a statistically significant benefit in preventing marked clinical worsening in all three domains as compared to placebo-treated patients.



“This is an excellent step forward for patients with Alzheimer’s disease”, said Professor Roy Jones, Director of the Research Institute for the Care of the Elderly, Bath, United Kingdom. “Ebixa has shown significant benefits in moderate to severe Alzheimer’s disease and it is at the moderate stage when most patients are currently diagnosed”.

Ebixa has also proven effective in reducing some of the core and most distressing symptoms of AD. Study results have demonstrated that Ebixa-treated patients experienced significant benefits in memory, language and the ability to perform daily activities. Furthermore, Ebixa has proven effective in significantly reducing levels of agitation/aggression, delusions and irritability in patients with AD.

The progression of Alzheimer’s disease is classified according to mild, moderate and severe stages. Moderate to severe disease, when symptoms become more apparent, is estimated to affect 80%(i) of diagnosed Alzheimer’s patients. This significant proportion of Alzheimer’s patients will now have access to this efficacious treatment for Alzheimer’s disease.

Camilla Dormer | alfa
Further information:
http://www.bm.com

More articles from Health and Medicine:

nachricht Dengue takes low and slow approach to replication
12.01.2018 | Duke University

nachricht Fast food makes the immune system more aggressive in the long term
12.01.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

Im Focus: Autoimmune Reaction Successfully Halted in Early Stage Islet Autoimmunity

Scientists at Helmholtz Zentrum München have discovered a mechanism that amplifies the autoimmune reaction in an early stage of pancreatic islet autoimmunity prior to the progression to clinical type 1 diabetes. If the researchers blocked the corresponding molecules, the immune system was significantly less active. The study was conducted under the auspices of the German Center for Diabetes Research (DZD) and was published in the journal ‘Science Translational Medicine’.

Type 1 diabetes is the most common metabolic disease in childhood and adolescence. In this disease, the body's own immune system attacks and destroys the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fachtagung analytica conference 2018

15.01.2018 | Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

 
Latest News

Black hole spin cranks-up radio volume

15.01.2018 | Physics and Astronomy

A matter of mobility: multidisciplinary paper suggests new strategy for drug discovery

15.01.2018 | Life Sciences

New method to map miniature brain circuits

15.01.2018 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>